Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Lung Neoplasms 76Leukemia, Myeloid, Acute 71Prostatic Neoplasms 67Neoplasm Metastasis 56Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 45Multiple Myeloma 44Colorectal Neoplasms 41Pancreatic Neoplasms 37Myelodysplastic Syndromes 35Carcinoma, Renal Cell 33Ovarian Neoplasms 31Melanoma 31Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Glioblastoma 27Triple Negative Breast Neoplasms 26Lymphoma, Large B-Cell, Diffuse 26Urinary Bladder Neoplasms 24Lymphoma 23Burkitt Lymphoma 22Squamous Cell Carcinoma of Head and Neck 21Glioma 20Fallopian Tube Neoplasms 20Carcinoma, Hepatocellular 18Mouth Neoplasms 17Leukemia, Biphenotypic, Acute 17Brain Neoplasms 17Sarcoma 16Oropharyngeal Neoplasms 16

Interventions

Peripheral Blood Stem Cell Transplantation 26Rituximab 20Cyclophosphamide 18fludarabine phosphate 17Mycophenolic Acid 16Tacrolimus 14Cyclosporine 14Whole-Body Irradiation 12Filgrastim 11Etoposide 10Radiotherapy 8Methotrexate 8Busulfan 8Therapeutics 7Methylprednisolone 7Antilymphocyte Serum 7Cladribine 6Lenalidomide 5Flow Cytometry 5obinutuzumab 4immunotoxin HA22 4Vorinostat 4Vemurafenib 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Ondansetron 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Cord Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Leukemia, Hairy Cell × Specimen Handling × Clear all
NCT06965114 2026-06-03

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 1/2 Recruiting
84 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT01841723 2026-05-13

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
44 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

NCT06311227 2026-05-13

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡